POLR2J: A Potential Drug Target and Biomarker (G5439)

Target Name: POLR2J

NCBI ID: G5439

POLR2J

POLR2J: A Potential Drug Target and Biomarker

POLR2J, short for poly (R2-ribose-1,6-beta-D-ribose) synthase, is a gene that encodes a protein involved in the synthesis of polyribose nucleotides (PRs), which are a type of sugar derived from the nucleotide base uracil. PRs have unique properties that make them an attractive research target in various fields, including drug development and cancer treatment. In this article, we will explore the potential of POLR2J as a drug target and biomarker.

POLR2J as a Drug Target

The polyribose nucleotide pathway is a promising target for drug development due to its involvement in various cellular processes, including DNA replication, RNA synthesis, and cell signaling. Polyribose nucleotides have been shown to play a critical role in cancer progression and treatment response. Therefore, targeting the polyribose nucleotide pathway has the potential to develop new treatments for various diseases.

POLR2J is a key enzyme involved in the polyribose nucleotide pathway. Its function is to catalyze the synthesis of PRs from the nucleotide base uracil. This process involves a series of biochemical steps, including the conversion of uracil to its phosphate derivative, UMP, by the enzyme Pyruvate Carrier Transporter (PCT), followed by the addition of a phosphate group to UMP by the enzyme Phosphoribosyl Pyruvate Carrier (PRPC). Pyruvate Carrier Transferase (PRT) then catalyzes the transfer of the phosphate group from PRT to UMP, resulting in the formation of PRs.

In recent years, researchers have discovered that aberrant levels of PRs can contribute to various diseases, including cancer. For example, increased PR levels have been observed in various types of cancer, including breast, ovarian, and prostate cancers. Therefore, targeting the polyribose nucleotide pathway, including the regulation of PR levels, may have implications for the development of new cancer treatments.

POLR2J as a Biomarker

POLR2J can also serve as a biomarker for various diseases. One of the significant advantages of PRs is their ability to be targeted by small molecules, making them an attractive target for drug discovery. By inhibiting the activity of PRR2J, researchers can reduce the production of PRs, which can lead to the formation of aberrant PR levels in cells. This can lead to the development of cellular models of disease that can be used to evaluate the efficacy of new treatments.

POLR2J has been shown to be involved in various cellular processes, including cell signaling, DNA replication, and cell survival. Therefore, it is a potential biomarker for various diseases. For example, decreased levels of PRR2J have been observed in cancer cells, which may indicate that these cells are less responsive to traditional cancer treatments. Additionally, increased levels of PRs have been observed in diseases that are associated with the polyribose nucleotide pathway, such as Alzheimer's and Parkinson's diseases. Therefore, monitoring the levels of PRs in these diseases may provide valuable information for the development of new treatments.

Conclusion

POLR2J is a gene that encodes a protein involved in the synthesis of polyribose nucleotides. Its function is to catalyze the synthesis of PRs from the nucleotide base uracil. In recent years, researchers have discovered that aberrant levels of PRs can contribute to various diseases, including cancer. Therefore, targeting the polyribose nucleotide pathway, including the regulation of PR levels, may have implications for the development of new cancer treatments. Additionally, POLR2J can also serve as a biomarker for various diseases. Further research is needed to fully understand the potential of POLR2J as a drug target and biomarker.

Protein Name: RNA Polymerase II Subunit J

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB11 is part of the core element with the central large cleft (By similarity)

The "POLR2J Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR2J comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets